Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $11.6K | $15.7K | $75.7K |
| Cost of revenue | $0 | $1.5K | $5.3K | $8.2K | $6.9K | $26.3K | $51.5K | $78.2K |
| Gross profit | $0 | −$1.5K | −$5.3K | −$8.2K | −$6.9K | −$14.7K | −$35.8K | −$2.4K |
| Gross margin | — | — | — | — | — | -127.3% | -229.0% | -3.2% |
| R&D | $1.7M | $2.1M | $2.9M | $2.4M | $1.6M | $1.4M | $1.2M | $670.9K |
| Operating income | −$6.1M | −$7.3M | −$7.4M | −$6.4M | −$5.4M | −$6.4M | −$5.7M | −$5.0M |
| EBITDA | $0 | −$7.3M | −$7.4M | −$6.4M | −$5.3M | −$6.1M | −$4.7M | −$3.9M |
| Net income | −$6.0M | −$7.8M | −$4.8M | −$2.7M | −$4.0M | −$6.6M | −$4.3M | −$7.0M |
| Net margin | — | — | — | — | — | -56802.8% | -27318.3% | -9221.4% |
| EPS (diluted) | -9.87 | -10.91 | -6.30 | -3.27 | -4.27 | -5.97 | -3.56 | -2.27 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $329M | $15.13 | $15.13–$15.13 | 1 |
| 2027 | $44M | $1.56 | $1.56–$1.56 | 1 |
| 2028 | $56M | $1.94 | $1.94–$1.94 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds ARTH.
No tracked institution reports a position in ARTH as of their last filing.
| Execution date | Ratio |
|---|---|
| 2023-01-18 | 1-for-200reverse |
| 2013-05-28 | 11-for-1 |
No one on the platform has traded ARTH yet.
| $117 |
| — |
| MDKMMDEChem, Inc. | $0.00 | -100.00% | $630 | — |
| MICRDMicron Solutions, Inc. | $0.00 | +0.00% | $317 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 5.1× sales vs its 944.5× historical median P/S.
Fair value ≈ $29.93 · price $0.16 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ARTH https://www.bizjournals.com/boston/news/2025/04/23/arch-therapeutics-files-chapter-11-bankruptcy.html?csrc=6398&utm_campaign=occ&utm_medium=fb&utm_source=ta&fbclid=IwY2xjawJ3U9VleHRuA2FlbQIxMQBicmlkETFqdlhkcjBkR2FHRFNtclFKAR5zohlqXO181_7nOrCg7U76GayNvpei7RXBEDrVmeSnX1dzRoyE9FmJh-5Xeg_aem_i61A3HKg8-jC4MjGvf_7xg
View on StockTwits ↗$ARTH I spy an increase in institutional ownership...
View on StockTwits ↗$ARTH what's brought this back to life, the fact they will be presenting at another conference?
View on StockTwits ↗HOTTEST STOCKS that have NEWS/ FILINGS Today! These are the stocks that you want to be watching this morning! $MGAM $ARTH $PSTV $CLOW $SGE
View on StockTwits ↗$ARTH Any news on this one? Just heard it recommended. Is it halted? Or just no volume?
View on StockTwits ↗$ARTH extended, again, completion of an uplist to Nasdaq market or nyse until March 15. Let’s hope it happens this year
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.